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Introduction: Transmyocardial laser revascularization is believed to
induce an angiogenic response within ischemic myocardium. We evalu-
ated transgene expression in the setting of transmyocardial laser revas-
cularization and hypothesized that intramyocardial injection of plasmid
DNA encoding the gene for vascular endothelial growth factor could
enhance the revascularization achieved by transmyocardial laser revas-
cularization, resulting in improved cardiac function. Methods: Ten
Yorkshire pigs had carbon dioxide–transmyocardial laser revascular-
ization or acupuncture sites with injections of an expression plasmid
encoding the gene for b -galactosidase with or without HVJ-liposomes.
Three days after transduction, transgene expression was determined by
enzyme-linked immunosorbent assay. Six weeks after placement of a
constrictor on the left circumflex artery, 29 pigs were randomized to
ischemic controls (n = 5), transmyocardial laser revascularization (n =
4), transmyocardial laser revascularization with expression plasmid b -
galactosidase injections (n = 5), expression plasmid-vascular endothelial
growth factor injections (n = 4), or transmyocardial laser revasculariza-
tion with expression plasmid-vascular endothelial growth factor (n = 5)
and harvested 6 weeks after therapy. Six transmyocardial laser revas-
cularization pigs had either expression plasmid b -galactosidase or
expression plasmid-vascular endothelial growth factor injections and
were harvested at 2 weeks. Normal pigs (n = 5) were included for com-
parison. Left ventricular free wall motion was assessed by a cardiologist
in a blinded manner. Results: Transgene expression did not vary signifi-
cantly with or without HVJ-liposomes in transfected transmyocardial
laser revascularization myocardium. However, expression was detected
in 56 of 60 (93%) transmyocardial laser revascularization–transfected
sites, but in only 10 of 20 (50%) non-transmyocardial laser revascular-
ization sites (P < .001). All (5 of 5 hearts) of the transmyocardial laser
revascularization–vascular endothelial growth factor treated hearts dis-
played no evidence of wall motion abnormalities. Only these hearts had
a statistically significantly different rate of wall motion abnormality
compared with ischemic controls (P = .004). Conclusion: Transfection
efficiency was improved with the use of transmyocardial laser revascu-
larization. Wall motion abnormalities were completely reversed within
6 weeks after transmyocardial laser revascularization with the direct
injection of an expression plasmid encoding vascular endothelial growth
factor. (J Thorac Cardiovasc Surg 1998;116:763-9)
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T he morbidity and mortality of ischemic heart dis-ease are directly attributable to an imbalance
between the heart’s oxygen delivery and consumption.
Transmyocardial laser revascularization (TMR) with a
high-energy carbon dioxide laser that creates channels
through the myocardial wall has recently been studied
in patients not amenable to conventional revasculariza-
tion procedures, resulting in symptomatic improve-
ment.1 However, there is mounting evidence that these
channels do not remain patent and that neovasculariza-
tion has been imputed to explain the observed thera-
peutic effects of TMR.2,3
The delivery of pro-angiogenic factors may enhance
this neovascularization, and direct gene transfer may
provide a means for effective delivery of such factors
to the target myocardium. Vascular endothelial growth
factor (VEGF), a 46-kd dimeric protein, has been
shown to promote new vessel formation in both nor-
mally perfused and ischemic tissues.4,5 Previous
attempts at viral-mediated gene transfer in the setting
of TMR have been associated with a significant inflam-
matory response with no evidence of enhanced trans-
gene expression.6 However, various forms of cellular
stress have been shown to enhance gene expression in
vitro. It has been established that in vivo direct gene
transfer with “naked” plasmid DNA (ie, DNA not asso-
ciated with the use of viral or viral-conjugate vectors)
is feasible in myocardial tissue, though transgene
expression occurs at low levels.7 We sought to define
the transduction capability of cells in this zone of injury
after TMR by quantifying the degree and the efficiency
of myocardial transgene expression with the use of
non-live viral vectors. The reporter gene b -galactosi-
dase in the form of either an expression plasmid or
incorporated in fusigenic hemagglutinating virus of
Japan (HVJ)-liposome complexes was used in the set-
ting of TMR with a high-energy carbon dioxide laser in
porcine myocardium. In addition, we hypothesized that
direct myocardial injection of plasmid DNA encoding
the gene for VEGF165 could enhance the revasculariza-
tion achieved by TMR in chronically ischemic porcine
hearts, resulting in improved cardiac function.
Materials and methods
Myocardial transfection studies
Left minithoracotomy. Ten Yorkshire pigs were premed-
icated with ketamine (10 mg/kg), intubated, and maintained
with general inhalational anesthesia with 2% isofluorane.
Cefazolin (40 mg/kg), MgSO4 (40 mg/kg), and bretylium
tosylate (10 mg/kg) were given intravenously as prophylaxis
against wound infection and atrial and ventricular arrhyth-
mias. A left anterior minithoracotomy was performed through
the fourth intercostal space, and the pericardium was incised
and suspended to reveal the free wall of the left ventricle.
Transesophageal echocardiogram. A transesophageal
ultrasonic probe was placed to visualize the left ventricular
wall motion and to confirm placement of transmural channels
by the carbon dioxide laser.
TMR. An 800-watt carbon dioxide laser was used to pro-
duce transmural channels discharging 16 J over a pulse width
of 20 ms.1-3 The channel density was approximately 1 chan-
nel/cm2 on the left ventricular free wall, being careful to
avoid the coronary vasculature. TMR areas were marked by
a 5-0 polypropylene stitch.
Gene delivery. Three equidistant 100 m L intramyocardial
injections were placed with a 25-gauge needle within 4 mm
of the TMR sites. Two vehicles, either fusigenic HVJ-lipo-
somes or naked plasmid were used to deliver an expression
plasmid (pSV) containing the gene encoding b -galactosidase
with an SV40 early promotor and enhancer. This promotor
has been determined to be similarly effective in driving trans-
gene expression in both ischemic and nonischemic myocardi-
um.7,8 Two doses of DNA each were used for myocardial
transfection: 5 and 15 m g for HVJ-liposomes and 100 and 200
m g for naked plasmid. Similar injections were placed around
22-gauge needle-puncture sites of non-TMR myocardium.
The protocol used for HVJ-liposome preparation has been
well described.9 A PGL2 expression plasmid, using an SV40
early promotor and enhancer, but encoding the gene for fire-
fly luciferase, was injected at TMR sites in an identical man-
ner for use as a control. For VEGF gene transfer experiments,
a pSV expression plasmid containing the gene-encoding
VEGF165 (pSV-VEGF165) with an SV40 early promotor and
enhancer was used (Fig 1).
Cardiectomy. Animals were killed 3 days after transduc-
tion. Two individual, 10-mm length, full-thickness myocar-
dial samples were taken at 5-mm intervals from each TMR
and injection site and snap frozen in liquid nitrogen. Sixty
samples from TMR-transfected myocardium and 20 samples
from non-TMR transfected myocardium, in addition to 20
control samples of TMR-luciferase transfected myocardium,
were taken for analysis.
Analysis of b -galactosidase expression. Samples were
homogenized with 0.25 mmol/L Tris-C1, pH 7.8, containing
0.1 mmol/L phenylmethylsufonyl fluoride, and centrifuged at
7500 rmax at 4°C for 30 minutes. b -Galactosidase protein
levels were assayed in extracts from tissue homogenates by
enzyme-linked immunosorbent assay, with subtraction of
background from TMR-myocardium transfected with
luciferase. These samples were normalized from protein by
Bradford protein assay. Data are represented in terms of
picograms of b -galactosidase produced per milligram of tis-
sue protein and expressed as mean ± SD. 
Chronically ischemic hearts
Left minithoracotomy, constrictor implantation. Forty
Yorkshire pigs (25 kg) were premedicated with ketamine (10
mg/kg), intubated, and maintained with general inhalational
anesthesia with 2% isofluorane. Cefazolin (40 mg/kg),
MgSO4 (40 mg/kg), and bretylium tosylate (10 mg/kg) were
given intravenously as prophylaxis against wound infection
and atrial and ventricular arrhythmias. With the use of the
sterile operative technique, a left anterior minithoracotomy
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was performed through the fourth intercostal space, and the
pericardium was incised and suspended to reveal the free
wall of the left ventricle, atrioventricular groove, and left cir-
cumflex artery. A 2.5-mm ameroid constrictor (Research
Instruments and Manufacturing, Corvallis, Ore) was placed to
visualize left ventricular wall motion before and after the
ameroid constrictor with rapid atrial pacing (Medtronic 5375
Demand Pulse Generator, Medtronic, Inc, Minneapolis,
Minn) to ensure adequate positioning of the ameroid con-
strictor and to document baseline left ventricular function
with and without stress/rapid atrial pacing.3 The pericardium
was approximated and chest wall was closed in anatomic lay-
ers. An ipsilateral transient 28F tube thoracostomy that had
been placed to suction was removed on extubation. Animals
were allowed to recover 6 weeks to permit occlusion of the
ameroid constrictor, with development of stable collateraliza-
tion. Of these 40 animals, 4 pigs experienced sudden cardiac
death at 14 to 17 days after ameroid constrictor implantation
with microinfarcts of the left ventricular free wall or antero-
lateral papillary muscle at autopsy. Additionally, 2 pigs were
killed because of joint effusions at 8 and 12 days after
ameroid constrictor implantation. The surviving animals
were randomized to the following groups (Fig 1):
Group I (ischemic controls, n = 5) had no further inter-
vention. 
Group II (TMR, n = 4) underwent TMR in the area at
risk at 6 weeks after ameroid constrictor implantation.
A transesophageal echocardiography (TEE) probe was
placed, and the ventricle rapidly paced to identify
areas at risk along the left ventricular free wall. Images
were digitally recorded for subsequent analysis by a
cardiologist in a blinded fashion. An 800-watt carbon
dioxide laser (Heart Laser; PLC Systems, Franklin,
Mass) was used to produce transmural channels dis-
charging 16 J over a pulse width of 20 ms. The chan-
nel density was approximately 1 channel/cm2 on the
left ventricular free wall, with care to avoid the coro-
nary vasculature. Channels were confirmed by TEE
and by pulsatile flow during systole. There were 15 to
18 TMR sites per heart, which were marked by 5-0
polypropylene stitches. 
Group III (TMR-gal, n = 5) underwent TMR at 6
weeks with 3 equidistant intramyocardial injections of
100 m g of a pSV encoding the gene for b -galactosidase
(pSV-b -galactosidase) surrounding each TMR site. 
Group IV (VEGF, n = 4) had sets of 3 equidistant
injections of 100 m g of an expression plasmid encod-
ing the gene for VEGF165, (pSV-VEGF165) without
TMR at 6 weeks. 
Group V (TMR-VEGF, n = 5) had TMR with each site
surrounded by 3 injections of 100 m g of pSV-VEGF165
at 6 weeks. All animals were harvested at 12 weeks
after ameroid constrictor placement. Six additional
pigs underwent TMR with either pSV-b galactosidase
or pSV-VEGF165 injections at 6 weeks but were har-
vested at 8 weeks (2 weeks after therapy). 
Group VI (n = 5) were age and weight-matched normal
Yorkshire pigs (45 kg) for comparison with groups I
through V at 12 weeks. 
All animals were given humane care in compliance with
the “Principles of Laboratory Animal Care” formulated by
the National Society for Medical Research, and the “Guide
for the Care and Use of Laboratory Animals” published by
the National Institutes of Health (NIH publication 86-23,
revised 1985).
Median sternotomy. Animals were killed via median ster-
notomy at 6 weeks after transduction and after TMR, or a
total of 12 weeks after ameroid constrictor implantation. TEE
and epicardial echocardiography was performed in the paced
and unpaced myocardium; images were recorded and stored
for analysis. Hearts were assessed for evidence of regional
wall motion abnormalities and overall ventricular function in
comparison with ischemic controls and age- and weight-
matched pigs.
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Fig 1. TMR with angiogenic gene therapy. Six weeks after ameroid constrictor placement, animals were ran-
domized into groups I through V. Therapy was administered in the area of reversible ischemia.
Statistical analysis. The data represented are expressed as
mean ± SD. Data were analyzed by 2-tailed Student’s t test
and by Fisher’s exact test with application of Bonferroni cor-
rections as indicated. 
Results
Transgene expression. Myocardial transgene expres-
sion was detected in 56 of 60 TMR-transfected sites 3
days after transfection (93%) but in only 10 of 20
(50%) non-TMR sites at the same time point (P < .001
by 2-tailed Fisher’s exact test).
The level of transgene expression did not vary signif-
icantly among delivery methods for TMR-transfected
sites at the doses tested. HVJ-liposomes yielded 992 ±
146 pg b -galactosidase/mg protein at doses of 5 m g/100
m L and 1211 ± 238 pg b -galactosidase/mg protein at 15
m g/100 m L. Similarly, naked plasmid yielded 1099 ±
322 pg b -galactosidase/mg protein at doses of 100
m g/100 m L, and 761 ± 179 pg b -galactosidase/mg pro-
tein at doses of 200 m g/100 m L. However, the level of
b -galactosidase expressed around TMR sites (987 ±
228 pg/mg) was approximately 2.4 times higher than
expression in non-TMR transfected sites with positive
expression (408 ± 148 pg/mg), P = .004 by 2-tailed
Student’s t test (Fig 2).
Functional analysis. Left ventricular free wall
motion in the area at risk was assessed by a cardiologist
in a blinded fashion. Hearts were scored as normal (no
regional wall motion abnormality, normal systolic
function) or abnormal (hypokinetic, dyskinetic or aki-
netic wall motion, or impaired systolic function). There
were no wall motion abnormalities either before or
immediately after ameroid constrictor placement. Six
weeks after treatment at harvest, all of the ameroid-
alone hearts had impaired wall motion (0/5 normal),
whereas 75% (3 of 4) of the TMR, 60% (3 of 5) of the
TMR-galactosidase hearts, and 50% (2 of 4) of the
VEGF hearts displayed evidence of persistent wall
motion abnormalities. Two of the 3 TMR-VEGF–treat-
ed hearts evaluated at 2 weeks after therapy had com-
pletely normal wall motion, whereas all 3 of the TMR-
b -galactosidase–treated hearts had persistent
abnormalities at the same time point. Those hearts with
impaired function were generally hypokinetic in the
areas at risk, with occasional areas of akinesia. There
were discrete focal abnormalities in 1 of the TMR-
treated hearts and 1 of VEGF-treated hearts, both of
which were scored as having normal overall wall
motion. In contrast, all (5 of 5) of the hearts treated
with TMR-VEGF displayed no evidence of regional
wall motion abnormality. Only the TMR-VEGF hearts
had a statistically significantly different rate of wall
motion abnormality compared with untreated ischemic
hearts (P = .0039 by 2-tailed Fisher’s exact test). 
Discussion
Direct injection of naked plasmid DNA has been most
successful in achieving transgene expression in striated
muscle tissue. Myocardium, in particular, displays the
ability to uptake foreign DNA at low, but predictable
levels of expression.10 The results of this study demon-
strate that direct non-viral gene transfer at sites of TMR
is feasible and that thermal injury associated with TMR
enhances both the efficiency and the degree of myocar-
dial transgene expression. Furthermore, the combined
use of TMR with the direct injection of a plasmid
encoding the gene for VEGF165 completely reversed
ischemic wall motion abnormalities within 6 weeks
after therapy in pigs that had previously undergone left
circumflex artery ameroid constrictor placement.
TMR represents the latest in a series of approaches
initially intended to directly revascularize ischemic
myocardium. Beck11 performed a myopexy, omen-
topexy, and poudrage; and Vineberg12 implanted the
internal thoracic artery into the myocardium for revas-
cularization. Sen and associates13,14 introduced acu-
puncture as a method to produce transmural channels.
Mirhoseini and Cayton15 developed the use of a low-
energy carbon dioxide laser to produce transmural
channels to directly perfuse the myocardium with ven-
tricular blood; later this was attempted with a holmi-
um:YAG laser. Failure of these techniques to produce
conclusive evidence of persistent myocardial revascu-
larization was thought to be related to immediate tissue
reapproximation after acupuncture and low laser energy
levels.2,15 A higher energy 800-watt carbon dioxide
laser discharging 16 J over a short pulse width (20 ms)
has been used recently in a multicenter trial to treat
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Fig 2.  Transgene expression level in positively reporting
sites of pSV-b -galactosidase transfected TMR and non-TMR
(acupuncture) myocardium after subtraction of background
from PGL2-luciferase transfected TMR myocardium. (Mean
± SD; P = .004 by 2-tailed Student’s t test). 
end-stage coronary artery disease. The patients select-
ed had advanced coronary artery disease that was not
amenable to conventional revascularization proce-
dures, and most of the patients had undergone either
coronary artery bypass grafting or percutaneous trans-
luminal coronary angioplasty.1 Collateral blood flow
was increased, and mean anginal scores were improved
over the 12-month period of observation after TMR,
with an operative mortality rate of 9%. Studies in both
human beings and animal models have revealed
increased subendocardial perfusion ratios.1-3 It appears
that an ongoing process of new microvessel growth and
a progressive recruitment of existing collaterals may
occur, stimulated by this interaction of the laser with
myocardial tissue. Other mechanisms, however, may
be important in the short-term symptomatic relief
observed in patients.16
The chromophore for the energy discharged from a
carbon dioxide laser is water.17,18 The central zone of
injury has been characterized as photochemical and is
surrounded by concentric photomechanical and pho-
tothermal zones of tissue injury. The photothermal zone,
with gradients between 40°C and 100°C, is character-
ized by sublethal cellular stress that may enhance plas-
mid uptake and subsequent gene expression17,18a (Fig 3).
Many cells in this zone survive, and our findings of
improved gene expression within this region imply that
not only is gene transfer compatible with TMR but that
TMR may actually improve the reliability of gene trans-
fer and the level of target protein expression achieved by
direct myocardial injection.
VEGF is synthesized by many cell types, but the
restriction of VEGF receptor expression yields relative
endothelial cell–specific mitogenicity.4,19 Both tissue
VEGF production and endothelial receptor density are
enhanced by regional ischemic insults, leaving the
ischemic zone more responsive to VEGF.5 VEGF and
basic FGF have been shown to improve collateral flow
from angiogenesis, with subsequent enhancement of
myocardial perfusion but inconsistent improvement of
regional myocardial function in ischemic models.
However, these previous studies have used in-dwelling
catheters, methods for slow release around coronary
vessels, or multiple repeated dosing to achieve signifi-
cance.20-23 The stability of the neovascularization
achieved by simple angiogenic factor therapy has not
been defined, nor have the risks of oncogenic transfor-
mation or stimulation of neo-intimal hyperplasia from
prolonged intravascular growth factor administration
been delineated for this approach.24,25 Because the
“naked” plasmid is injected locally in our approach, a
greater spatial restriction on plasmid-mediated trans-
gene expression diminishes the possibility of signifi-
cant uncontrolled regional or systemic exposure that
exists with viral-based gene delivery systems that have
been tested.26 Furthermore, plasmid-mediated gene
therapy may allow a single injection of a gene encod-
ing a proangiogenic agent to produce sustained local
protein production, which could act in a paracrine fash-
ion and obviate the need for repeated administration of
the protein.7,27
The process of new blood vessel growth is complex
and known to involve multiple growth factors and the
up-regulated expression of multiple receptors on
endothelial and other vascular cells.23,28 The simple
delivery of a single factor may therefore be insufficient
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Fig 3. Pathologic effects in myocardial tissue of carbon dioxide laser application.
to achieve maximal therapeutic effect. TMR with its
controlled local tissue injury is likely to stimulate this
broader range of pro-angiogenic responses, including
the local inflammation that has been shown to play a
critical role in the stimulation of both capillary and
larger vessel growth.28 The combination of TMR and
specific growth factor over-expression may therefore
be particularly synergistic. Such an effect would not be
achieved by the simple injection of either a single pro-
tein or gene encoding for its production. Additionally,
the progressive nature of the response of ischemic
myocardium to TMR may potentially be protective in
the genetically modified heart should this level of
genetically induced vascularity not be stable over time.
Currently, we are quantifying the degree of collateral-
ization achieved with this combined therapy, and fur-
ther studies will be required to evaluate the stability of
functional improvement and to establish the long-term
efficacy of genetic enhancement of myocardial tissue.
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Discussion
Dr Todd Rosengart (New York, NY). At last year’s AATS
meeting we presented data in the same porcine ischemia
model where we demonstrated complete reversal of wall
motion abnormalities with the administration of an aden-
ovirus with VEGF alone. In light of these findings, I have
several questions for you. First, did you, as part of your study
design, somehow handicap your VEGF therapy so you could
bring out additional benefits in conjunction with TMR? If so,
do you think you could further optimize your VEGF therapy
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so that you would get an improved angiogenic effect with
VEGF therapy alone? 
Second, do you think these data confirm the speculation
that TMR works by inducting angiogenesis? If this is the
case, do you think the role of TMR will eventually be as a
source of inflow for angiogenic therapy or do you see anoth-
er role for TMR in the future?
Dr Sayeed-Shah. In response to your first question, the
genetically altered hearts treated with the plasmid encoding
VEGF165 alone did show improvement in regional contractil-
ity in focal areas within the region of reversible ischemia
although this improvement was primarily seen in unstressed
hearts and became inconsistent and non-uniform during rapid
pacing–induced stress. These findings seem to confirm obser-
vations by others that, although myocardial collateral vessel
development and blood flow seem to improve with gene ther-
apy alone, actual functional improvement has been much
more difficult to demonstrate.
It has been suggested that arteriogenesis, or the develop-
ment of larger inflow vessels, may need to be stimulated
before an actual functional improvement may be demonstrat-
ed. Dr Hardy has shown that the inflammatory process relat-
ed to TMR application induces a prolonged monocyte infil-
tration. As Dr Wolfgang Schaper’s work suggests, tissue
responses to inflammatory stimuli that regulate monocyte
activity to elaborate matrix metalloproteinases and induce
fibroblast growth factor activity may be more closely related
to arteriogenesis. In theory, this promotion of larger, “inflow
vessels” may complement the angiogenesis mediated by
VEGF, which is more typically seen in ischemic myocardi-
um. This may, in part, explain the significantly improved
function seen in the TMR-VEGF group.
There is a growing body of evidence that suggests TMR
may act in the long-term by inducing a pro-angiogenic state,
although other mechanisms may also be involved in produc-
ing the short-term symptomatic relief observed in patients. We
chose to use a naked plasmid vehicle for these studies to mit-
igate the possibility of adverse tissue or immunologic respons-
es that have been well documented by a number of groups to
occur with viral vector administration, while retaining the
ability to effectively transduce myocardial tissue. In addition,
the relative spatial and temporal restriction on plasmid-med-
icated gene transfer was perceived to be beneficial in the set-
ting of TMR because we sought to amplify a localized tissue
response of recruitment of coronary microvasculature to a
functionally significant level, without enhancing the potential
for adverse or uncontrolled local or systemic angiogenesis.
Dr Charles R. Bridges (Philadelphia, Pa). Please com-
ment on the fact that, in your study in the TMR-alone group,
you did not see an improvement in wall motion abnormalities
in the TMR-alone group, which is at variance with your own
statement about the fact that TMR has a salutary effect on
perfusion in the absence of any additional gene therapy.
The gold standard in angiogenesis research (eg, Unger and
associates) has used a similar model in both canine and
porcine animal models where ameroid constrictors have been
placed on the circumflex or left anterior descending artery.
However, in their research, microsphere studies were used to
document improvement in blood flow; in addition, it has gen-
erally been coupled with some histologic evidence of angio-
genesis. Did you perform those studies? And if so, what did
you find?
Dr Sayeed-Shah. In response to your first question, this
discrepancy is a matter of time frame and was 1 of our pri-
mary reasons for combining these 2 treatment modalities.
With TMR, the improvement in blood flow to ischemic
myocardium has been demonstrated in both clinical studies
and recent animal studies at 3 months and significantly so at
6 months after therapy. This implies the existence of a pro-
gressive process of revascularization that we also did not find
to be significant at only 6 weeks after therapy in our animals.
One potential advantage of this combined approach with
TMR with gene therapy therefore would be in the accelera-
tion of this process that we have observed in these animals at
6 weeks after therapy. Given that the stability of the pro-
angiogenic response to gene therapy has not been deter-
mined, this addition of the observed progressive recruitment
of microvasculature seen with TMR may be of further thera-
peutic benefit in the long term.
With respect to your second question, we are awaiting the
results of the histopathologic samples collected from all the
animals but do not have data to report at this time. We are
currently performing a series of experiments designed to
specifically evaluate regional myocardial blood flow by
radioactive microspheres and by magnetic resonance imag-
ing.
Dr Robert C. Robbins (Stanford, Calif). The functional
data are impressive, but what about the transfection efficiency
that you saw that was so high in the hearts with TMR. Do you
have any insight into why your transfection efficiency was so
much improved?
Dr Sayeed-Shah. Thermal gradients applied to cell culture
lines in vitro have been shown to improve trandsuction effi-
ciency. We have previously demonstrated that transmyocar-
dial thermal injury may enhance gene uptake and expression
in a rat model of heterotopic heart transplantation. Dr
Thomsen has shown that tissue vaporization processes char-
acteristic of infrared lasers mimic this type of injury in the
myocardium with similar thermal fluence patterns.
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